

Oriol Casanovas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4453768/publications.pdf>

Version: 2024-02-01

81
papers

7,032
citations

117453

34
h-index

82410

72
g-index

82
all docs

82
docs citations

82
times ranked

11348
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | High <i>FGFR1</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149. | 3.2 | 12 |
| 2 | Promalignant effects of antiangiogenics in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 199-206. | 4.3 | 3 |
| 3 | Diffuse optical platform for the personalization of plasmonic photothermal therapy. , 2022, , . | | 0 |
| 4 | EV11 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 300. | 1.7 | 9 |
| 5 | Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits. <i>EMBO Molecular Medicine</i> , 2020, 12, e11889. | 3.3 | 4 |
| 6 | Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. <i>Oncologist</i> , 2019, 24, 38-46. | 1.9 | 23 |
| 7 | Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents. <i>Cancer Research</i> , 2019, 79, 5328-5341. | 0.4 | 21 |
| 8 | RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v217. | 0.6 | 0 |
| 9 | Mechanisms of Anti-angiogenic Therapy. , 2019, , 183-208. | | 0 |
| 10 | Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834. | 1.7 | 41 |
| 11 | Quantification of gold nanoparticle accumulation in tissue by two-photon luminescence microscopy. <i>Nanoscale</i> , 2019, 11, 11331-11339. | 2.8 | 17 |
| 12 | Non-invasive and quantitative <i>in vivo</i> monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies. <i>Nanoscale</i> , 2019, 11, 5595-5606. | 2.8 | 5 |
| 13 | Insulin-like growth factor levels and chronic lymphocytic leukaemia: results from the MCC Spain and EpiLymphSpain studies. <i>British Journal of Haematology</i> , 2019, 185, 608-612. | 1.2 | 1 |
| 14 | Mechanisms of Tumor Angiogenesis. , 2019, , 3-31. | | 2 |
| 15 | ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1216-1229. | 1.1 | 75 |
| 16 | A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 532-543. | 1.9 | 28 |
| 17 | Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. <i>Nature Communications</i> , 2018, 9, 4826. | 5.8 | 53 |
| 18 | Unraveling the Role of Angiogenesis in Cancer Ecosystems. <i>Frontiers in Oncology</i> , 2018, 8, 248. | 1.3 | 204 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018, 128, 3887-3905. | 3.9 | 79 |
| 20 | Angiogenesis and Metabolism: Entwined for Therapy Resistance. <i>Trends in Cancer</i> , 2017, 3, 10-18. | 3.8 | 46 |
| 21 | Sprouting strategies and dead ends in anti-angiogenic targeting of NETs. <i>Journal of Molecular Endocrinology</i> , 2017, 59, R77-R91. | 1.1 | 9 |
| 22 | Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749. | 2.6 | 34 |
| 23 | Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. <i>Targeted Oncology</i> , 2017, 12, 19-35. | 1.7 | 77 |
| 24 | Translational research in neuroendocrine tumors: pitfalls and opportunities. <i>Oncogene</i> , 2017, 36, 1899-1907. | 2.6 | 26 |
| 25 | Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics. <i>Biomedical Optics Express</i> , 2017, 8, 2563. | 1.5 | 5 |
| 26 | The TGF β 2 pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. <i>International Journal of Cancer</i> , 2016, 139, 1894-1903. | 2.3 | 53 |
| 27 | Therapeutic Benefit of Selective Inhibition of p110 α PI3-Kinase in Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 5805-5817. | 3.2 | 35 |
| 28 | Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. <i>Cell Reports</i> , 2016, 15, 1134-1143. | 2.9 | 96 |
| 29 | Antiangiogenic resistance via metabolic symbiosis. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1211979. | 0.3 | 3 |
| 30 | Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study. <i>Annals of Oncology</i> , 2016, 27, vi145. | 0.6 | 1 |
| 31 | Scanning, non-contact, hybrid broadband diffuse optical spectroscopy and diffuse correlation spectroscopy system. <i>Biomedical Optics Express</i> , 2016, 7, 481. | 1.5 | 9 |
| 32 | The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. <i>Oncotarget</i> , 2016, 7, 60110-60122. | 0.8 | 16 |
| 33 | MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. <i>Oncotarget</i> , 2016, 7, 9271-9287. | 0.8 | 31 |
| 34 | Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research. <i>Current Drug Targets</i> , 2016, 17, 1728-1734. | 1.0 | 10 |
| 35 | A non-contact, small animal scanner based on diffuse optical spectroscopy and diffuse correlation spectroscopy. , 2016, , . | | 0 |
| 36 | Simultaneous, non-invasive measurement of local tissue hemodynamics, oxygen metabolism and gold nanorod concentration in vivo. , 2016, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015, 26, 1987-1993. | 0.6 | 112 |
| 38 | A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer. <i>Carcinogenesis</i> , 2015, 36, 792-799. | 1.3 | 18 |
| 39 | PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. <i>Nature Communications</i> , 2015, 6, 7935. | 5.8 | 86 |
| 40 | Multi-target angiokinase inhibitors to fight resistance. <i>Cell Cycle</i> , 2014, 13, 2649-2650. | 1.3 | 4 |
| 41 | Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. <i>EMBO Molecular Medicine</i> , 2014, 6, 539-550. | 3.3 | 21 |
| 42 | The PDGFR β -AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 658-667. | 3.2 | 55 |
| 43 | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 345-351. | 2.7 | 29 |
| 44 | Antiangiogenic Therapies: Going beyond Their Limits. <i>Cancer Discovery</i> , 2014, 4, 31-41. | 7.7 | 90 |
| 45 | Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. <i>Nature Communications</i> , 2014, 5, 5054. | 5.8 | 17 |
| 46 | Relevance of Angiogenesis in Neuroendocrine Tumors. , 2014, , 29-41. | | 2 |
| 47 | ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , 2013, 133, 235-246. | 2.3 | 16 |
| 48 | Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. <i>BMC Cancer</i> , 2013, 13, 382. | 1.1 | 21 |
| 49 | Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. <i>Journal of Internal Medicine</i> , 2013, 273, 128-137. | 2.7 | 53 |
| 50 | Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. <i>Clinical Cancer Research</i> , 2013, 19, 2842-2849. | 3.2 | 80 |
| 51 | Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. <i>International Journal of Cancer</i> , 2013, 133, 2464-2472. | 2.3 | 76 |
| 52 | Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. <i>Oncogene</i> , 2013, 32, 3732-3743. | 2.6 | 46 |
| 53 | Inhibition of the p110 β isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. <i>Journal of Experimental Medicine</i> , 2013, 210, 1937-1945. | 4.2 | 56 |
| 54 | Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. <i>Journal of Experimental Medicine</i> , 2013, 210, 563-579. | 4.2 | 110 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Study on activation of the IGF-1R mTOR pathway in neuroendocrine tumours (NETs).. Journal of Clinical Oncology, 2013, 31, 4139-4139. | 0.8 | 4 |
| 56 | Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Cell Biology, 2013, 200, i10-i10. | 2.3 | 0 |
| 57 | Inhibition of the p110 β isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Cell Biology, 2013, 202, 202701A99. | 2.3 | 0 |
| 58 | Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer. EMBO Molecular Medicine, 2012, 4, 168-170. | 3.3 | 6 |
| 59 | Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF β -VEGFR2 signalling. Nature, 2012, 484, 110-114. | 13.7 | 315 |
| 60 | Limitations of therapies exposed. Nature, 2012, 484, 44-46. | 13.7 | 42 |
| 61 | Relevance of angiogenesis in neuroendocrine tumors. Targeted Oncology, 2012, 7, 93-98. | 1.7 | 10 |
| 62 | Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Journal of Clinical Investigation, 2012, 122, 1832-1848. | 3.9 | 154 |
| 63 | Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4394-4399. | 3.3 | 222 |
| 64 | Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma. International Journal of Oncology, 2011, 39, 543-52. | 1.4 | 3 |
| 65 | The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis. Radiation Oncology, 2011, 6, 6. | 1.2 | 5 |
| 66 | Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. Cancer Research, 2011, 71, 4214-4225. | 0.4 | 67 |
| 67 | Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy. Hormone and Metabolic Research, 2011, 43, 884-889. | 0.7 | 35 |
| 68 | The adaptive stroma joining the antiangiogenic resistance front. Journal of Clinical Investigation, 2011, 121, 1244-1247. | 3.9 | 13 |
| 69 | Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2. Journal of Biological Chemistry, 2010, 285, 10748-10760. | 1.6 | 75 |
| 70 | Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research, 2009, 15, 3384-3395. | 3.2 | 57 |
| 71 | Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell, 2009, 15, 220-231. | 7.7 | 2,168 |
| 72 | Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647. | 1.9 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | New drug development in digestive neuroendocrine tumors. <i>Annals of Oncology</i> , 2007, 18, 1307-1313. | 0.6 | 27 |
| 74 | Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. <i>Oncogene</i> , 2005, 24, 6597-6604. | 2.6 | 30 |
| 75 | Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. <i>Cancer Cell</i> , 2005, 8, 299-309. | 7.7 | 1,478 |
| 76 | P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. <i>Oncogene</i> , 2004, 23, 7537-7544. | 2.6 | 44 |
| 77 | The p21Cip1 protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating livers. <i>Hepatology</i> , 2002, 35, 1063-1071. | 3.6 | 19 |
| 78 | Osmotic Stress Regulates the Stability of Cyclin D1 in a p38SAPK2-dependent Manner. <i>Journal of Biological Chemistry</i> , 2000, 275, 35091-35097. | 1.6 | 131 |
| 79 | Calmodulin Binds to p21Cip1 and Is Involved in the Regulation of Its Nuclear Localization. <i>Journal of Biological Chemistry</i> , 1999, 274, 24445-24448. | 1.6 | 53 |
| 80 | The Protein SET Regulates the Inhibitory Effect of p21Cip1 on Cyclin E-Cyclin-dependent Kinase 2 Activity. <i>Journal of Biological Chemistry</i> , 1999, 274, 33161-33165. | 1.6 | 78 |
| 81 | The Cell Cycle Inhibitor p21CIP1s Phosphorylated by Cyclin A-CDK2 Complexes. <i>Biochemical and Biophysical Research Communications</i> , 1997, 241, 434-438. | 1.0 | 15 |